Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence.

00:55: The challenges of liver disease

04:44: How Lexogen supports NGS drug discovery

07:29: Major transcriptomics developments

10:05: Designing high quality AI data

15:47: How the Ochre-Lexogen partnership began

17:17: Why a specialist partner is essential for scale

18:21: Lexogen delivers on the massive sequencing project

21:50: Why high quality data is crucial

27:02: Lexogen's role in AI discovery

34:51: Future plans and directions

This episode was produced with the support of Lexogen. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Labiotech. Innehållet i podden är skapat av Labiotech och inte av, eller tillsammans med, Poddtoppen.